Ensign Group Q2 profit beats on higher occupancy rates
Reuters2026/07/27 10:17
Overview
US skilled nursing operator's Q2 revenue rose 17%, adjusted EPS beat analyst expectations
Adjusted EPS for Q2 rose 21% year-over-year, beating consensus
Company raised 2026 annual earnings and revenue guidance after strong Q2 results
Outlook
Ensign raises 2026 annual EPS guidance to $7.75-$7.85 from $7.48-$7.62
Company raises 2026 annual revenue guidance to $5.87 bln-$5.92 bln from $5.81 bln-$5.86 bln
Company expects to maintain a healthy pace of acquisitions through Q3 2026
Result Drivers
OCCUPANCY AND SKILLED MIX - Higher occupancy rates and increased skilled mix revenue and days drove growth, per CEO Barry Port
ACQUISITIONS - Addition of 20 new operations, including real estate assets, contributed to revenue growth, per Chief Investment Officer Chad Keetch
CLINICAL OUTCOMES - Superior CMS quality ratings and lower rehospitalization rates supported demand and financial results
Company press release: ID:nGNX45dC0G
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Rental Revenue |
|
$7.98 mln |
|
Q2 Adjusted EPS |
Beat |
$1.92 |
$1.84 (4 Analysts) |
Q2 EPS |
|
$1.68 |
|
Q2 Net Income |
|
$99.83 mln |
|
Q2 Operating Income |
|
$122.50 mln |
|
Q2 Service Revenue |
|
$1.43 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities services peer group is "buy"
Wall Street's median 12-month price target for Ensign Group, Inc is $222.38, about 28.6% above its July 24 closing price of $172.99
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 26 three months ago
Reuters Recommended Reads
July 24 - HCA Healthcare Q2 revenue rises on Medicaid programs; narrows outlook
July 25 - US measles cases hit 35-year high as vaccinations decline
July 24 - US FDA approves over-the-counter Tylenol combination pill for pain relief
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto Liquidity Is Moving – Here’s Where the Money Is Going

Fed Rate Hike Odds Jump to 87% as FOMC Meeting Nears

Next 1000x Meme Coin Race: 7 Top Coins to Watch as Apeing’s 10% Referral Rewards Raise the Stakes
